| Not Yet Recruiting | Vapor Ablation for Localized Cancer Lesions NCT03514329 | Uptake Medical Technology, Inc. | N/A |
| Not Yet Recruiting | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer NCT07285148 | Beijing Pearl Biotechnology Limited Liability Company | Phase 1 / Phase 2 |
| Recruiting | Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study) NCT07243132 | GFPC Investigation | — |
| Not Yet Recruiting | Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer NCT06622174 | Houda Bahig | Phase 1 |
| Recruiting | Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatme NCT06781905 | Hospices Civils de Lyon | — |
| Recruiting | Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients NCT06481813 | Nantes University Hospital | N/A |
| Recruiting | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Recruiting | Exercise as Maintenance Therapy in Advanced Lung Cancer NCT06513663 | Indiana University | N/A |
| Recruiting | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer NCT06343402 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Withdrawn | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 NCT05703555 | Erasmus Medical Center | Phase 2 |
| Recruiting | Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients NCT06032052 | Hubei Cancer Hospital | Phase 2 |
| Recruiting | Definitive Radiation for High-Risk Spine Metastases NCT06165419 | Stony Brook University | Phase 2 |
| Completed | CALM: Managing Distress in Malignant Brain Cancer NCT06180460 | Virginia Commonwealth University | N/A |
| Recruiting | Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613 | Obsidian Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer NCT05846594 | Hoffmann-La Roche | N/A |
| Recruiting | Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer NCT05502913 | Soroka University Medical Center | Phase 2 |
| Completed | Emulation of the KEYNOTE-189 Trial Using Electronic Health Records NCT05908799 | Aetion, Inc. | — |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Terminated | Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies NCT05408871 | Yale University | Phase 1 |
| Recruiting | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors NCT05544240 | Williams Cancer Foundation | Phase 1 |
| Recruiting | The Impact of Radiotherapy on Oligometastatic Cancer NCT05933876 | Institut Investigacio Sanitaria Pere Virgili | — |
| Recruiting | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation NCT05609578 | Mirati Therapeutics Inc. | Phase 2 |
| Active Not Recruiting | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With E NCT05256290 | Black Diamond Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 | Blueprint Medicines Corporation | Phase 1 |
| Recruiting | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzu NCT05143970 | Institut Paoli-Calmettes | Phase 1 |
| Recruiting | LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBER NCT04790682 | Institut Curie | N/A |
| Active Not Recruiting | Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer NCT04940325 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Completed | Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study NCT04804137 | University Hospital, Tours | — |
| Unknown | DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criter NCT04708483 | Hyperfusion | N/A |
| Completed | Piloting Pathways With Lung Cancer Patients NCT04161157 | Laurie McLouth | N/A |
| Completed | Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer NCT03867175 | Wake Forest University Health Sciences | Phase 3 |
| Completed | Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic L NCT03721120 | Centre Leon Berard | N/A |
| Withdrawn | McMaster Catheterization for Thoracoscopic Surgery Study NCT02640326 | McMaster University | N/A |
| Completed | Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE) NCT03198468 | Uptake Medical Technology, Inc. | N/A |
| Active Not Recruiting | Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases NCT03143322 | UNICANCER | N/A |
| Completed | A Study of ASN007 in Patients With Advanced Solid Tumors NCT03415126 | Asana BioSciences | Phase 1 |
| Completed | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) NCT03345810 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC NCT03177291 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers NCT03073473 | Cota Inc. | — |
| Completed | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC NCT03044626 | AIO-Studien-gGmbH | Phase 2 |
| Terminated | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease NCT02469701 | howard safran | Phase 2 |
| Completed | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal o NCT02310464 | OBI Pharma, Inc | Phase 1 |
| Terminated | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advan NCT02109016 | Clovis Oncology, Inc. | Phase 2 |
| Unknown | The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel NCT01814150 | Gottfried Maya | — |
| Completed | Safety and Efficacy of Cryoablation for Metastatic Lung Tumors NCT01307501 | Boston Scientific Corporation | N/A |
| Completed | Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously NCT01543672 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Unknown | A Study to Assess PV-10 Chemoablation of Cancer of the Liver NCT00986661 | Provectus Biopharmaceuticals, Inc. | Phase 1 |